HIV Monoclonal Antibodies


This technology describes several hybridomas that produce monoclonal antibodies (mAbs) useful in HIV research applications. The mAbs are specific for either gp41 or gp120. In particular, the hybridomas producing mAbs designated D19, D56, M12, T8 and T24 (all anti-gp120), and T32 and T33 (gp41 specific) were found to be of particular utility. Additional hybridomas expressing mAbs disclosed in the publications may also be available.

Potential Commercial Applications: Competitive Advantages:
  • HIV research
 


Development Stage:
  • Murine hybridomas available
  • T32 mAb available


Related Invention(s):
E-200-1993-1


Inventors:

Patricia Earl (NIAID)  ➽ more inventions...

Christopher Broder (NIAID)  ➽ more inventions...

Robert Doms (NIAID)  ➽ more inventions...

Bernard Moss (NIAID)  ➽ more inventions...


Intellectual Property:
Research Tool (anti-gp41mAbs) -- Patent protection is not being pursued for this technology.

Publications:
Earl PL, et al PMID 9060620
Earl PL, et al. PMID 7512157
Earl PL, et al. US Patent 6,039,957
Earl PL, et al. US Patent 6,171,596

Collaboration Opportunity:

The National Institute of Allergy and Infectious Dieases, Laboratory of Viral Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV Monoclonal Antibodies. Please contact either Michael Pizali or Dana Hsu at 301-496-2644 for more information.


Licensing Contact:
Benjamin Hurley, Ph.D.
Email: benjamin.hurley@nih.gov
Phone: 240-669-5092

OTT Reference No: E-109-2008-0
Updated: May 18, 2018